Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCP | P55072 | 15/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10164538 | 0.94 | ALDH1A1 (0.37) | VCPTRPA1MEN1KMT2AALDH1A1 | |
| SCHEMBL10164546 | 0.93 | CYP2C9 (0.41) | MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL10164560 | 0.91 | ALDH1A1 (0.42) | TRPA1KMT2AALDH1A1LMNA | |
| SCHEMBL10202205 | 0.91 | VCP (0.44) | VCPTRPA1 | |
| SCHEMBL893858 | 0.91 | VCP (0.44) | VCPTRPA1 | |
| SCHEMBL10164609 | 0.90 | TRPA1 (0.38) | TRPA1MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL10164672 | 0.89 | TRPA1 (0.34) | VCPTRPA1MEN1KMT2AALDH1A1 | |
| SCHEMBL10164505 | 0.86 | L3MBTL1 (0.46) | TRPA1ALDH1A1LMNA | |
| SCHEMBL10164586 | 0.86 | LMNA (0.41) | TRPA1MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL894607 | 0.85 | TRPA1 (0.40) | VCPTRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120083474-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083474-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | TRPA1, TRPV1, TRPV2 | VCP 2458/4885TRPA1 1/4885MEN1 4531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.